Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTR1E | P28566 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426755 | 0.98 | HTR1E (0.33) | LMNASMN1; SMN2HSP90AA1HSP90AB1MGLL | |
| SCHEMBL6424495 | 0.90 | PTGS2 (0.37) | LMNAHSP90AA1HSP90AB1MGLLMAPT | |
| SCHEMBL6424118 | 0.89 | KMT2A (0.33) | LMNAMGLLHTR1ES1PR3ALDH1A1 | |
| SCHEMBL6426919 | 0.89 | PTGS2 (0.37) | LMNAMGLLHTR1ES1PR3ALDH1A1 | |
| SCHEMBL6424446 | 0.88 | PTGS1 (0.42) | LMNASMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL5558666 | 0.87 | KMT2A (0.33) | LMNASMN1; SMN2MGLLHTR1ES1PR3 | |
| SCHEMBL6424805 | 0.86 | PTGS1 (0.42) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL6423862 | 0.85 | PTGS2 (0.43) | LMNAMGLLMAPTKMT2AMEN1 | |
| SCHEMBL6425701 | 0.84 | PTGS2 (0.39) | — | |
| SCHEMBL5560858 | 0.83 | PTGS2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | LMNA 3613/4885SMN1; SMN2 4408/4885HSP90AA1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.